Tinea%20capitis%20(pediatric) Patient Education

Patient Education

Educate the patient/guardian about the contagiousness of the disease
- Explain that sharing of toys or personal objects (eg combs and hairbrushes) can spread the infection, thus should be avoided
- Identify and treat asymptomatic carriers including family members, caretakers and playmates
- Treat or remove animals or pets infected with M canis
- Disinfect belongings of infected patients such as hairbrushes, combs, beddings, etc
Reassure the parent/caregiver that patients receiving appropriate treatment for tinea capitis may attend school 1 week after initiation of treatment if infection is caused by anthropophilic species (T tonsurans, T violaceum, T soudanense, M audouinii) or immediately if caused by other dermatophytes
Haircuts, shaving of the head and wearing a cap during treatment are usually unnecessary
Follow-up visits are needed for assessment of treatment response
Close contacts of patients exhibiting symptoms may consider testing, since fungal infections caused by anthropophilic species are highly contagious

Product Highlight - Mac Dual-Action

12 Sep 2023

Hexylresorcinol 2.4 mg lozenge

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.

The gold standard amino acid formula for infants with cow’s milk allergy

24 Jul 2019

Cow’s milk allergy (CMA) is one of the most common forms of childhood food allergy, affecting 2% to 3% of infants in the first year of life.¹ Although more prevalent in formula-fed infants, exclusively breast-fed infants can also develop CMA due to exposure to cow’s milk protein via the maternal diet.^2,3 In general, up to 80% to 90% of children with CMA develop tolerance by three years of age.²